Instil Bio Inc TIL.OQ TIL.O is expected to show no change in quarterly revenue when it reports results on May 8 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Instil Bio Inc is for a loss of $2.59 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Instil Bio Inc is $110.00, above its last closing price of $14.05.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -3.26 | -3.22 | -1.82 | Beat | 43.5 |
Sep. 30 2024 | -2.33 | -2.11 | -3.54 | Missed | -68 |
Jun. 30 2024 | -2.99 | -2.98 | -2.29 | Beat | 23.2 |
Mar. 31 2024 | -2.22 | -2.23 | -3.74 | Missed | -67.7 |
Dec. 31 2023 | -2.29 | -2.84 | -1.99 | Beat | 30.1 |
Sep. 30 2023 | -1.98 | -2.00 | -10.40 | Missed | -420 |
Jun. 30 2023 | -3.47 | -3.27 | -2.80 | Beat | 14.3 |
Mar. 31 2023 | -3.09 | -3.10 | -8.80 | Missed | -183.9 |
This summary was machine generated May 6 at 13:54 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。